Dr. Wayne R. Danter, MD, FRCPC
Dr. Wayne Danter is the founder of 123Genetix Inc. and he is a pioneer at the evolving interface between artificial intelligence (“AI”) and pharmacogenomics (i.e., the study of how genetics affect a person's response to drugs). Dr. Danter is first person in the world to have drug go to clinical trials 100% evolved from AI. Dr. Danter has conducted extensive research on the medical application of AI technologies to disease diagnosis, outcome prediction, precision oncology, artificial stem cells and artificial organoids. His research has been published in many peer-reviewed journals and he has been an invited presenter and panelist at numerous international meetings.
Prior to founding 123Genetix, Dr. Danter was the President, CEO, CSO and Director of Critical Outcome Technologies Inc., which he also founded. While at Critical Outcome Technologies, he invented a proprietary, AI-based technology platform that utilizes a series of predictive computer models to identify compounds with a high probability of successful development from disease specific drug discovery and chemical optimization through preclinical and early clinical testing. Dr Danter is also the inventor of the ROSALIND A.I. platform for Precision Oncology.
Dr. Danter is a board certified in Internal Medicine with additional training in Clinical Pharmacology and Critical Care. Dr Danter was also a member of the Royal College of Physicians of Canada examination board for specialist licensure in Internal Medicine.
Web: www.123Genetix.com